Novartis AG
NVS
$164.58
$1.911.17%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.34B | 13.91B | 14.05B | 13.23B | 13.15B |
| Total Other Revenue | 524.00M | 449.00M | 782.00M | 387.00M | 405.00M |
| Total Revenue | 13.86B | 14.36B | 14.84B | 13.62B | 13.56B |
| Cost of Revenue | 3.54B | 3.54B | 3.32B | 3.22B | 3.31B |
| Gross Profit | 10.32B | 10.82B | 11.52B | 10.40B | 10.25B |
| SG&A Expenses | 3.44B | 3.30B | 3.44B | 3.06B | 3.50B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 190.00M | 70.00M | -4.00M | 148.00M | -890.00M |
| Total Operating Expenses | 10.01B | 9.77B | 9.37B | 8.80B | 8.25B |
| Operating Income | 3.86B | 4.59B | 5.46B | 4.82B | 5.31B |
| Income Before Tax | 3.22B | 4.20B | 4.53B | 4.41B | 3.29B |
| Income Tax Expenses | 814.00M | 266.00M | 507.00M | 798.00M | 465.00M |
| Earnings from Continuing Operations | 2.40B | 3.93B | 4.02B | 3.61B | 2.82B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 5.00M | -2.00M | 17.00M | -3.00M | -2.00M |
| Net Income | 2.41B | 3.93B | 4.04B | 3.61B | 2.82B |
| EBIT | 3.86B | 4.59B | 5.46B | 4.82B | 5.31B |
| EBITDA | 4.96B | 5.78B | 6.56B | 5.91B | 6.41B |
| EPS Basic | 1.26 | 2.04 | 2.07 | 1.83 | 1.42 |
| Normalized Basic EPS | 1.14 | 1.39 | 1.66 | 1.46 | 1.66 |
| EPS Diluted | 1.25 | 2.02 | 2.06 | 1.82 | 1.41 |
| Normalized Diluted EPS | 1.13 | 1.38 | 1.65 | 1.45 | 1.65 |
| Average Basic Shares Outstanding | 1.91B | 1.93B | 1.95B | 1.97B | 1.99B |
| Average Diluted Shares Outstanding | 1.93B | 1.94B | 1.96B | 1.98B | 2.00B |
| Dividend Per Share | 4.67 | -- | -- | -- | 3.86 |
| Payout Ratio | 0.00% | -- | 61.49% | 147.89% | 0.00% |